Specialist Allergy & Gastroenterology Service

Eosinophilic Oesophagitis (EoE)

Expert diagnosis and personalised treatment for EoE — a chronic, immune-mediated condition of the food pipe — delivered by our specialist allergy team in the UK.

►  Book a Consultation

✓ BSG 2022 Guidelines✓ Biologic Therapy Available✓ Multidisciplinary Team✓ Dietary & Endoscopy Support

Understanding the Condition

What is Eosinophilic Oesophagitis?

Eosinophilic Oesophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the oesophagus (food pipe). It is characterised by an abnormal build-up of eosinophils — a type of white blood cell — in the lining of the oesophagus, causing progressive inflammation, tissue remodelling, and impaired swallowing function.

Unlike typical acid reflux, EoE is an immune-mediated, Type 2 inflammatory condition closely linked to food allergens and environmental triggers. The current estimated prevalence is approximately 34 per 100,000 people in the UK, though diagnosis rates are rising as awareness and testing methods improve. EoE is more common in males and is strongly associated with other atopic conditions including asthma, eczema, and allergic rhinitis.

Without appropriate treatment, EoE can lead to oesophageal strictures (narrowing), fibrous scarring, and severe swallowing difficulties. Early specialist involvement is essential to prevent long-term structural damage.

Key fact: Eosinophils are not normally present in the oesophagus. A finding of 15 or more eosinophils per high-powered field (HPF) on biopsy is the accepted diagnostic threshold, as set by international consensus guidelines (ACG 2025; BSG/BSPGHAN 2022).


Recognising EoE

Symptoms of Eosinophilic Oesophagitis

Symptoms vary considerably by age and may overlap with acid reflux or other oesophageal conditions, which often leads to delayed diagnosis. The following are common presentations:

Adults

  • Difficulty swallowing (dysphagia)
  • Food bolus obstruction (food stuck in the throat)
  • Chest pain or pressure
  • Heartburn unresponsive to antacids
  • Avoiding hard or dry foods
  • Eating very slowly or drinking excess fluids with meals

Children & Adolescents

  • Feeding difficulties or refusal
  • Poor weight gain or faltering growth
  • Vomiting or regurgitation
  • Abdominal or chest pain
  • Choking or gagging with textured foods
  • Persistent heartburn-like symptoms

⚠ Emergency: If food becomes completely stuck in the oesophagus and does not pass within two hours, this is a food bolus obstruction. Please attend your nearest Emergency Department immediately. EoE is the most common underlying cause of this condition.


Causes & Triggers

What Causes EoE?

The exact cause of EoE is multifactorial, involving genetic predisposition, immune dysregulation, and environmental exposures. Crucially, EoE is a non-IgE-mediated (delayed) food allergy, which means standard allergy skin-prick tests and specific IgE blood tests are not reliable for identifying food triggers. Diagnosis and trigger identification require endoscopic biopsy and structured dietary assessment.

The six most common food protein triggers, recognised by the British Dietetic Association and NHS specialist centres, are:

Cow's Milk

Wheat & Gluten

Egg

Soya

Seafood (Fish & Shellfish)

Nuts & Seeds

Not all six triggers are relevant to every patient. Our dietitians use structured elimination and reintroduction protocols — including the Six Food Elimination Diet (SFED) and Four Food Elimination Diet (FFED) — to identify your individual triggers safely and effectively.


The Diagnostic Pathway

How is EoE Diagnosed?

Diagnosis requires a combination of clinical assessment and endoscopic biopsy. The BSG/BSPGHAN (2022) and ACG (2025) guidelines define EoE as:

  • Symptoms of oesophageal dysfunction (dysphagia, food bolus, reflux unresponsive to standard therapy)
  • ≥15 eosinophils per HPF on oesophageal biopsy samples
  • Exclusion of other conditions that may cause oesophageal eosinophilia

1

Specialist Consultation

Our allergist takes a comprehensive history including atopic background, symptom duration, dietary patterns, and previous treatments.

2

Upper GI Endoscopy & Biopsy

Upper gastrointestinal endoscopy (gastroscopy) with multiple oesophageal biopsies from the proximal, mid, and distal oesophagus. Typical endoscopic features include furrows, rings (trachealization), white exudates, and strictures, graded using the EREFS scoring system.

3

Histopathology

Biopsy samples are analysed by a specialist pathologist. Diagnosis is confirmed when peak eosinophil count reaches or exceeds 15 eosinophils/HPF, with careful exclusion of GORD, coeliac disease, and other eosinophilic gastrointestinal disorders.

4

Multidisciplinary Review

Confirmed cases are reviewed by our multidisciplinary team (allergist, gastroenterologist, specialist dietitian) to formulate an individualised treatment and monitoring plan.


Treatment Options

How We Treat Eosinophilic Oesophagitis

Treatment for EoE is personalised and may combine dietary, pharmacological, endoscopic, and biological approaches. Current management is guided by the ACG Clinical Guidelines (2025), BSG/BSPGHAN Guidelines (2022), and updated UpToDate protocols (May 2026).

1. Dietary Elimination Therapy

Dietary therapy remains a cornerstone of EoE management and is the only strategy that directly targets causative triggers without medication. Our specialist dietitians supervise structured elimination and reintroduction protocols:

  • Six Food Elimination Diet (SFED): Removes milk, wheat, egg, soya, seafood, and nuts simultaneously. Foods are reintroduced sequentially (one at a time) with repeat endoscopy after each reintroduction to confirm remission or identify triggers.
  • Four Food Elimination Diet (FFED): A targeted alternative based on clinical history and symptom pattern.
  • Step-up approach: Starting with the most common single trigger (milk) before broadening elimination, to minimise dietary restriction.

Dietary treatment for adults is typically supervised for 6 weeks per phase; 8–12 weeks for children (BDA FASG guidelines).

2. Proton Pump Inhibitors (PPIs)

High-dose PPIs (e.g., omeprazole, lansoprazole) are a first-line option in both adults and children. Although EoE is not an acid-mediated condition, PPIs have demonstrated anti-inflammatory properties that can reduce oesophageal eosinophilia in a subset of patients. They are well tolerated and may be used alone or in combination with other therapies. Clinical response is reassessed by repeat endoscopy and biopsy.

3. Swallowed Topical Corticosteroids

Swallowed fluticasone or budesonide preparations act directly on the oesophageal mucosa and are effective in reducing eosinophilic inflammation. They are the most widely used pharmacological treatment for active EoE. Topical steroids carry a low systemic side-effect profile when used correctly. Orodispersible budesonide tablets (Jorveza®) are now available in the UK and offer a patient-friendly delivery mechanism optimised for mucosal contact.

4. Biologic Therapy — Dupilumab (Dupixent®)

Latest Treatment Advance

Dupilumab (Dupixent®) is a monoclonal antibody targeting the IL-4 receptor alpha subunit, thereby blocking both IL-4 and IL-13 — the key cytokines driving Type 2 inflammation in EoE. It is currently the first and only biologic approved for the treatment of EoE in adults and adolescents aged 12 years and over (weighing ≥40 kg).

The Phase 3 LIBERTY EoE TREET trial demonstrated significant histological and symptomatic improvement compared to placebo. Real-world data published in 2026 confirm sustained endoscopic and histologic remission in both adult and paediatric patients across multiple centres.

New data presented at the 2026 Digestive Disease Week (DDW) conference demonstrated that dupilumab can improve oesophageal calibre within 6 months — a structural benefit equivalent to oesophageal dilatation — reinforcing its role as a potential disease-modifying therapy.

Dupilumab is administered as a subcutaneous injection every two weeks. It is particularly beneficial for patients with concomitant atopic conditions (eczema, asthma) where a single biologic can treat multiple Type 2 inflammatory diseases simultaneously. Our team can assess your suitability and assist with access pathways in the UK.

5. Endoscopic Oesophageal Dilatation

For patients who have developed oesophageal strictures or fibrous narrowing, endoscopic dilatation can mechanically widen the oesophagus and provide meaningful symptomatic relief. Dilatation does not address the underlying inflammation and should therefore be used alongside anti-inflammatory treatment. It is performed by our endoscopy team under careful monitoring.


Long-Term Care

Monitoring & Long-Term Management

EoE is a chronic, relapsing condition. Even patients who achieve remission require ongoing monitoring to detect disease recurrence, assess for oesophageal remodelling, and optimise long-term quality of life. International expert consensus guidelines (2023) recommend regular clinical review with endoscopic and histological reassessment as part of routine monitoring.

Our clinic uses validated outcome measures including the:

  • EREFS (Endoscopic Reference Score) — grades mucosal features at endoscopy
  • I-SEE (Index of Severity for Eosinophilic Oesophagitis) — a validated clinical severity index
  • Dysphagia symptom questionnaires (DSQ) — patient-reported swallowing outcomes
  • Peak eosinophil count per HPF on repeat biopsy

Treatment goals include histological remission (<15 eos/HPF), resolution of symptoms, and prevention of oesophageal fibrosis and stricture formation.


The Allergy Connection

EoE and Allergic Disease

EoE sits firmly within the spectrum of Type 2 immune-mediated conditions. Up to 70% of patients with EoE have at least one co-existing atopic condition. EoE is considered part of the “allergic march” alongside atopic dermatitis, IgE-mediated food allergy, allergic rhinitis, and asthma.

Importantly, oral food immunotherapy (OIT) — used in IgE-mediated food allergy desensitisation — is a recognised risk factor for triggering or exacerbating EoE, particularly with milk, egg, and shellfish OIT. Patients undergoing OIT at our clinic are monitored for EoE development as part of our standard safety protocols.

Our allergy specialists are trained to manage EoE both as an isolated diagnosis and as part of complex multi-system allergic disease — ensuring a joined-up approach to all aspects of your immune health.


Frequently Asked Questions

Common Questions About EoE

Is EoE the same as acid reflux (GORD)?

No. Although both conditions share symptoms such as heartburn and difficulty swallowing, they are distinct diseases with different mechanisms. EoE is immune-mediated, not acid-driven. Many patients with EoE are initially misdiagnosed with GORD and do not respond to standard acid-suppression therapy. If your reflux symptoms have not responded to PPIs, EoE should be considered and investigated with endoscopy.

Can EoE be cured?

There is currently no cure for EoE. However, the condition can be effectively managed and put into remission with the right treatment. Many patients maintain excellent quality of life with dietary modification, medication, or biologic therapy. Ongoing monitoring is required as EoE may relapse when treatment is stopped.

Will a skin-prick test or IgE blood test identify my EoE triggers?

No. EoE is a non-IgE-mediated, delayed allergic reaction. Standard allergy tests — including skin-prick tests (SPT) and specific IgE blood tests — are unreliable for identifying food triggers in EoE. Trigger identification requires a structured elimination diet with endoscopic confirmation. Our team will guide you through this process safely.

Can children have EoE?

Yes. EoE was first described in children and affects approximately 50 per 100,000 children in the UK. Symptoms in younger children often present as feeding refusal, poor growth, or vomiting rather than the swallowing difficulties more typical in adults. Our team has experience managing EoE across all age groups, including paediatric cases in collaboration with paediatric gastroenterology and dietetic colleagues.

How do I access dupilumab (Dupixent®) for EoE in the UK?

Dupilumab can be prescribed by specialist clinicians for eligible patients (adults and adolescents ≥12 years, ≥40 kg) who meet criteria based on disease severity and previous treatment history. Our team will assess your suitability and guide you through the access process, including any relevant funding or prior authorisation requirements. Private prescribing is available at our clinic.


Medical References

1. Dellon ES, Muir AB, Katzka DA et al. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Oesophagitis. Am J Gastroenterol. 2025;120(1):31–59.

2. Lucendo AJ, Molina-Infante J, Árias Á et al. BSG/BSPGHAN Consensus Guidelines on EoE. Gut. 2022;71(8):1459–1487.

3. Arnim UV, Biedermann L, Aceves SS et al. Monitoring Patients with EoE in Routine Clinical Practice — International Expert Recommendations. Clin Gastroenterol Hepatol. 2023;21(10):2526–2533.

4. Lim WK et al. Dupilumab normalises the EoE disease transcriptome. J Allergy Clin Immunol. 2026 Apr 22 [Online ahead of print]. doi:10.1016/j.jaci.2026.01.033.

5. Hoang TT et al. Real-world outcomes of dupilumab for treatment of EoE. J Can Assoc Gastroenterol. 2026. doi:10.1093/jcag/gwaf042.191.

6. Regeneron/Sanofi. Dupixent demonstrates improved oesophageal function in EoE Phase 4 Trial. DDW 2026 late-breaking oral presentation. May 2026.

7. British Dietetic Association — Food Allergy Specialist Group (FASG). Six Food Elimination Diet for EoE patient guidance. 2019 (updated).

8. Guts UK. Eosinophilic Diseases patient information. Published April 2025; reviewed April 2028.

Concerned You or Your Child May Have EoE?

Our specialist allergy team offers prompt assessment, expert diagnosis, and access to the latest treatments including biologic therapy. Referrals accepted from GPs and self-referrals welcome.

►  Book an Appointment ☎  Call Us

This page is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. UK Allergy Clinic | www.ukallergy.com | Page last reviewed June 2026.

Copyright 2026. All Rights Reserved

LAIC Main Menu
LAIC Main Menu